SymbolRNXT
NameRENOVORX, INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Pharmaceutical Preparations
Address4546 EL CAMINO REAL,SUITE B1, LOS ALTOS, California, 94022, United States
Telephone+1 650 284-4433
Fax
Email
Websitehttps://www.renovorx.com
IncorporationUNDEFINED
Incorporated On
Employees
Fiscal Year
Public Since
ExchangesNASDAQ
Auditor
Audit StatusNOT PROVIDED
Reporting Status
CIK0001574094
Description

RenovoRx Inc is a clinical-stage biopharmaceutical company. It is focused on developing therapies for the local treatment of solid tumors and conducting a Phase 3 registrational trial for lead product candidate RenovoGem.

Additional info from NASDAQ:
RenovoRx Inc is a clinical-stage biopharmaceutical company. It is focused on developing therapies for the local treatment of solid tumors and conducting a Phase 3 registrational trial for lead product candidate RenovoGem.

2026-08-13 17:08

New Form 8-K/A - RenovoRx, Inc. <b>Filed:</b> 2026-08-13 <b>AccNo:</b> 0001193125-26-349157 <b>Size:</b> 705 KB <br />Item 2.02: Results of Operations and Financial Condition <br />Item 9.01: Financial Statements and Exhibits

Read more
2026-08-12 20:16

(90% Positive) RENOVORX, INC. (RNXT) Reports Q3 2026 Financial Results

Read more
2026-08-12 20:06

RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth

Read more
2026-08-11 12:30

RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer

Read more
2026-08-11 12:30

RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer

Read more
2026-08-06 12:30

RenovoRx Announces First Commercial Clinical Use ofRenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors

Read more
2026-08-06 12:30

RenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors

Read more
2026-08-04 12:30

RenovoRx to Highlight TAMP™ Platform at JonesTrading Virtual Key Opinion Leader Webinar on the Evolving Pancreatic Cancer Landscape, August 13th

Read more
2026-08-04 12:30

RenovoRx to Highlight TAMP™ Platform at JonesTrading Virtual Key Opinion Leader Webinar on the Evolving Pancreatic Cancer Landscape, August 13th

Read more
2026-07-29 12:30

RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET

Read more